TNF and Cowden disease: A total of 5 RCTs including 866 TNF antagonist-experienced patients with moderate-to-severe CD evaluated maintenance clinical remission after treatment with Adalimumab (n = 1 trial), Ustekinumab (n = 2 trials), Vedolizumab (n = 2 trials, included one trial evaluating Vedolizumab SC).